Time and predictors of response to tumour necrosis factor- blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort
Open Access
- 12 April 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (7) , 1361-1366
Abstract
Objective. To determine predictors and time to response to treatment with TNF-α blockers in patients with PsA in a longitudinal observational cohort. Methods. We performed a cohort analysis of patients who were followed prospectively in a large PsA clinic. Response to treatment was defined as an improvement of at least 40% in active (tender and/or swollen) and swollen joint count (SJC) and 50% improvement in the Psoriasis Area and Severity Index (PASI) score. Results. Ninety-five patients were included in the analysis. Of the total patients, 72.6 and 77.9% demonstrated 40% improvement in active joint counts at 3 and 12 months, respectively. Also, 80.5 and 87.4% of the patients showed 40% improvement in SJC at 3 and 12 months, respectively. A PASI50 was achieved by 54 and 60.4% after 3 and 12 months of treatment, respectively. Of 17 patients who did not achieve 40% improvement in total SJC at 3 months, 11 (64.7%) responded at 12 months. In multivariate analysis, the number of swollen joints at baseline predicted response of total active joints at 12 months [odds ratio (OR) 1.34; P = 0.02], whereas past use of TNF-α blocker decreased odds of response (OR 0.05; P = 0.01). Conclusion. TNF-α blockers are effective in most PsA patients with the majority responding within 3 months of treatment. A significant proportion of the early non-responders will have a delayed response to treatment. Higher SJC at baseline and no prior use of TNF-α blockers predict response.Keywords
This publication has 12 references indexed in Scilit:
- Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled studyArthritis & Rheumatism, 2009
- Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexateAnnals of the Rheumatic Diseases, 2008
- Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexateAnnals of the Rheumatic Diseases, 2007
- Classification criteria for psoriatic arthritis: Development of new criteria from a large international studyArthritis & Rheumatism, 2006
- Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2005
- Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnnals of the Rheumatic Diseases, 2005
- Psoriatic arthritis treatment: biological response modifiersAnnals of the Rheumatic Diseases, 2005
- Psoriatic arthritis assessment tools in clinical trialsAnnals of the Rheumatic Diseases, 2005
- Guideline for anti-TNF-α therapy in psoriatic arthritisRheumatology, 2005
- Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progressionArthritis & Rheumatism, 2004